北京若生智能科技有限公司
Drug Database
CL

clomiphene citrate (Omifin / Clomid)

✓ Approved

Sanofi S.A · 小分子 · 小分子

什么是 clomiphene citrate？

clomiphene citrate 是一种小分子，由Sanofi S.A研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Omifin, Clomid
公司Sanofi S.A
药物类别小分子
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Sanofi S.A

治疗适应症

clomiphene citrate 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Reproductive system and breast disordersInfertility female✓ Approved

相关研究文献

PubMedInternational journal of molecular sciences2026-10-27

Association of Circulating microRNAs in Plasma with Coronary Collateral Circulation in Patients with Chronic Total Occlusion.

Kiseleva Anna A, Sotnikova Evgeniia E, Zharikova Anastasia A, Vasilev Dmitry D et al.

Chronic total occlusion (CTO) occurs in 16-52% of patients with coronary artery disease (CAD) and is often accompanied by variable development of coronary collateral circulation (CCC). The aim of this work was to study the associations between circulating plasma microRNAs (miRNAs) and the development of CCC in patients with CTO. This exploratory study included 43 patients: a control group-patients without significant coronary artery stenosis (n = 20), and two CTO groups with good (n = 13) and poor (n = 10) CCC based on the Rentrop classification. The study was performed simultaneously on two types of plasma samples (K2EDTA and sodium citrate). Total RNA was isolated using the miRNeasy Serum/Plasma Advanced Kit. Libraries were prepared using the QIAseq miRNA UDI Library Kit and then sequenced on the NextSeq 550 using a 1 × 75 bp protocol. A total of 18 miRNAs were found to be differentially expressed (DE) in EDTA plasma and 13 in citrate plasma; only one miRNA in citrate plasma (hsa-miR-92a-3p) was differentially expressed between the good and poor CCC groups. However, given the limited sample size, the findings should be considered hypothesis-generating, and further studies are required for validation in larger, independent cohorts and to establish the roles of these miRNAs in CCC development.

PMID 42941886
阅读全文 →
PubMedThe journal of poultry science2026-10-27

Effects of Cyclic High Ambient Temperature on Tricarboxylic Acid Cycle Intermediates and Orotate Levels in the Liver and Breast Muscle of Broiler Chickens.

Katafuchi Ayumi A, Shimamoto Saki S, Tomonaga Shozo S, Kamimura Miyu M et al.

Heat stress alters tricarboxylic acid (TCA) cycle metabolism in broiler chickens; however, quantitative changes in TCA cycle-related metabolites remain poorly understood. This study determined the effects of heat exposure on TCA cycle intermediate (citrate, isocitrate, α-ketoglutarate, succinate, fumarate, and malate) and orotate levels in the liver and breast muscle of broiler chickens. Twelve 14-day-old male broiler chickens were assigned to either a control group (25 ± 1 °C) or a cyclic high ambient temperature group (35 ± 1 °C for 8 h/day) and reared under these conditions for 4 days. Heat exposure increased liver levels of citrate, α-ketoglutarate, fumarate, and malate, while decreasing succinate and orotate. Heat exposure also decreased the mRNA expression of isocitrate dehydrogenase 3A (IDH3A) and oxoglutarate dehydrogenase, key TCA cycle regulatory enzymes, as well as dihydroorotate dehydrogenase and ubiquinol-cytochrome c reductase Rieske iron-sulfur protein 1 (UQCRFS1), which are involved in mitochondrial electron transport. Heat exposure increased breast muscle levels of succinate, fumarate, and malate, while reducing IDH3A and UQCRFS1 mRNA expression. These findings suggest that heat exposure impairs TCA cycle metabolism in broiler chickens, possibly by reducing the utilization of TCA cycle intermediates through impaired electron transfer in mitochondrial complex III.

PMID 42936156
阅读全文 →
PubMedClinical kidney journal2026-10-27

Short-term effects of an SGLT2 inhibitor on divalent ions in autosomal dominant polycystic kidney disease: a randomized crossover trial.

Roth Lorena L, Harmacek Dusan D, Schachtner Thomas T, George Britta B et al.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a cornerstone of chronic kidney disease therapy, reducing disease progression, cardiovascular events, and mortality. Autosomal dominant polycystic kidney disease (ADPKD) patients were excluded from major trials, and data on electrolyte handling with SGLT2 inhibitors, in combination with tolvaptan, are lacking. SIDIA was a randomized, double-blind, placebo-controlled, two-period crossover trial in 15 adults with ADPKD (mean estimated glomerular filtration rate (eGFR) 68 ml/min/1.73 m²; median age 43 years). Participants received empagliflozin 10 mg or placebo for 14 days, separated by a 2-week washout. The primary endpoint was 24 h urinary and fractional excretion of phosphate, calcium, and magnesium. Exploratory secondary endpoints included markers of kidney stone propensity, inflammation, vitamin D metabolism, and tolerability. Treatment effects were estimated using generalized linear mixed models. Given the small sample size, analyses were exploratory and focused on effect estimation. For the primary endpoint, neither 24 h urinary nor fractional excretion of phosphate, calcium, or magnesium differed between empagliflozin and placebo. Empagliflozin lowered serum uric acid (-26%), increased serum magnesium (+5.7%) and urinary citrate (+78.6%), and reduced blood pressure (-4/-7 mmHg). An expected decline in eGFR (-7.1%) was observed, with no major short-term safety signals observed. Copeptin levels increased with empagliflozin (+26%). In this exploratory mechanistic trial, no substantial short-term difference in urinary or fractional excretion of divalent ions were detected with empagliflozin. The observed changes in serum magnesium, urinary citrate, uric acid, and copeptin are hypothesis-generating and require confirmation in larger, longer-term studies.

PMID 42936265
阅读全文 →
PubMedMetabolites2026-10-27

Linking Stone Mineral Composition to 24-Hour Urinary Metabolic Profiles: An Episode-Based Cohort Study.

Sun Shiwei S, Liu Jiang J, Qiao Yi Y, Wang Dong D et al.

Stone composition reflects the urinary environment in which calculi form, whereas 24 h urine testing identifies modifiable lithogenic abnormalities. This study examined component-specific urinary metabolic profiles and evaluated whether routine clinical and urinary variables could distinguish common stone minerals. This retrospective study included 256 patients undergoing 297 stone surgeries, consolidated into 256 treatment episodes. Fourier-transform infrared spectroscopy identified stone minerals, which were linked to preoperative 24 h urine profiles. Calcium oxalate monohydrate (COM), calcium oxalate dihydrate (COD), carbonate apatite, and anhydrous uric acid were evaluated using multivariable logistic regression. Mutually exclusive calcium oxalate-calcium phosphate phenotypes, nested cross-validated prediction models, and unsupervised clustering were also examined. COM, COD, carbonate apatite, and anhydrous uric acid were present in 78.5%, 73.0%, 39.5%, and 9.8% of episodes, respectively. Higher urine pH was associated with carbonate apatite (odds ratio [OR] per standard deviation, 1.78; 95% confidence interval [CI], 1.33-2.38), whereas lower pH was associated with anhydrous uric acid (OR, 0.26; 95% CI, 0.11-0.58). Higher urinary citrate was associated with COM, but phenotype analysis showed that hypocitraturia increased from 45.3% in calcium oxalate-only episodes to 60.7% in mixed calcium oxalate-calcium phosphate episodes and 89.5% in calcium phosphate episodes without calcium oxalate. Lower urine volume was associated with COD. Cross-validated areas under the curve ranged from 0.654 to 0.712, and metabolic clusters showed substantial mineral overlap. Urine pH provided the clearest component-specific signal, whereas citrate associations depended on accompanying minerals. Routine 24 h urine testing complemented but did not replace direct stone analysis.

PMID 42941187
阅读全文 →
PubMedSexual medicine2026-10-27

Understanding patient perspectives and preferences on sildenafil orodispersible formulation: a survey-based evaluation of men using erectile dysfunction medications.

Sansone Andrea A, Mondello Malvestiti Franco M P FMP, Mantegazza Raffaella R, Vignesh Shivani Ohri SO et al.

Erectile dysfunction (ED) is a common disease condition with major psychosocial and clinical consequences. Over 50% of men aged 40 years and above are estimated to experience some level of ED. Phosphodiesterase type 5 inhibitors (PDE5Is) remain the mainstay of ED treatment. Sildenafil citrate orodispersible film (ODF) is a novel formulation designed to improve convenience and patient satisfaction. This study explored real-world perspectives and patient preferences regarding the use of sildenafil citrate ODF. A cross-sectional, web-based survey was conducted in Italy (September-November 2024) in adult men using prescription ED medications. Data on demographics, lifestyle, clinical condition, treatment experiences, and patient perceptions about PDE5Is with a focus on sildenafil ODF were collected. The survey included 276 men (mean age 47 years; 43.5% Viagra users, 25% Cialis users, 13.4% other branded ED medication users, and 18.1% generic ED medication users). Most were married (51%), employed (78%), and reported at least one comorbidity (75%), predominantly cardiovascular (53%). Film-coated tablets of PDE5 inhibitors were the most used formulation (72%), while 5% reported sildenafil ODF use.Awareness of sildenafil ODF was high, with valued attributes including water-free administration, portability, discretion, and faster perceived onset of action. Among overall ED medication users, 79% expressed willingness to adopt sildenafil ODF with 33% citing liking of the formulation and 28% citing perceived difference from already using medication. The main barrier to adoption was high cost compared to other ED medications, cited by 37% of the 21% participants who did not express willingness to adopt sildenafil ODF. Sildenafil ODF was widely perceived by patients as a discreet and practical alternative to conventional film-coated tablets, with high willingness for adoption. Aligning treatment choices with patient preferences may enhance adherence, satisfaction, and overall quality of life in ED management.

PMID 42936858
阅读全文 →
PubMedAnimals : an open access journal from MDPI2026-10-27

Mitochondrial Dysfunction Across Multiple Organs in Broilers Exhibiting Wooden Breast Myopathy.

Shakeri Majid M, Chatterjee Debolina D, Rafieian-Naeini Hamid Reza HR, Kim Woo Kyun WK et al.

Wooden breast (WB) in broilers has been linked to impaired mitochondrial function in the breast muscle. When mitochondrial function declines, organs receive less ATP and experience oxidative stress. Muscle development is linked to the optimal function of the gut, liver, and pancreas, which depends on adequate ATP to support nutrient absorption and metabolism. The effects of the WB myopathy on other organs and tissues within broilers are relatively unknown. The aim of this study was to investigate factors linked to mitochondrial function in multiple organs from broilers exhibiting WB. From sixty 8-week-old broilers, ten severe WB and ten normal breast muscles were selected for tissue collection (liver, pancreas, three sections of intestine, and breast muscle). Reduced citrate synthase activity and mitochondrial complex-II activity were observed in the muscle, pancreas, liver and duodenum tissues of WB broilers compared to normal broilers. Broilers with WB had reduced glutathione content in the pancreas and all three sections of the intestine when compared to normal broilers. Whole tissue ATP content was decreased in the muscle and liver of WB broilers. Overall, these data suggest that mitochondrial function may be impaired in tissues beyond just the breast muscle in broilers that exhibit the WB myopathy.

PMID 42939216
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多clomiphene citrate